secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001516551-25-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience Q4 net loss $9.7M; Phase 2a obesity trial top-line data accelerated to late Q3 2025
--------------------------------------------------------------------------------

- Cash $68.4M at Dec 31, 2024; projected runway through at least Q1 2027.
- Phase 2a CBeyond trial enrolled 136 patients; interim analysis removed; data expected late Q3/early Q4 2025.
- Net loss FY2024 $26.6M vs $37.6M in 2023 (prior year included $21.2M IPR&D charge).
- R&D expense FY2024 $18.7M (up from $5.8M) driven by Phase 2 trial and manufacturing costs.
- Settled insurance litigation, received $2.0M cash proceeds in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/0001516551-25-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/skye-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001516551-25-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer